



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: **Oliver Yoa-Pu Hu et al.**)
Serial No. **10/079,416**) Group Art Unit: **14**
Filing Date: **February 22, 2002**) Examiner: **Vickie Y. Kim**
For: **DERMAL CYTOCHROME**) Customer No.
P450 1A INHIBITORS AND
ENHANCERS)
Atty. Docket No. **39297-174170**)

RECEIVED
TECH CENTER 1600
MAR 20 2003
26694
26694
PATENT TRADEMARK OFFICE
3/20/B

March 18, 2003

Honorable Commissioner for Patents
Washington, D.C. 20231

AMENDMENT UNDER 37 C.F.R. § 1.111

Sir:

In response to the Office Action dated December 18, 2002, Applicants request the entry of the following amendments and remarks into the subject application:

IN THE CLAIMS:

Please amend claim 1 as follows:

Claim 1. (Once Amended). A dermal cytochrome P450 1A (CYP1A) inhibitor, wherein said dermal CYP1A inhibitor is a compound selected from the group consisting of (-)-epicatechin, (+)-epicatechin, (+)-limonene, 3-phenylpropyl acetate, α -naphthoflavone, apigenin, baicalein, baicalin, β -myrcene, catechin, β -naphthoflavone, cineole, daidzein, daidzin, diosmin, ergosterol, formononetin, gallic acid, genistein, glycyrrhizin, glycyrrhizic acid, hesperetin, hesperidin, isoquercitrin, kaempferol, lauryl alcohol, luteolin, luteolin-7-glycoside, narigin, nordihydroguaiaretic acid, oleanolic acid,